Wave Life Sciences

WVE · Nasdaq · Singapore / United States

Share price · WVE

$2.77-2.52 (-47.64%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when WVE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-8.3%
  2. 1 Oct 2026+4.9%
  3. 17 Aug 2026-5.9%

    Nothing announced by WVE that day or the session before.

  4. 11 Aug 2026-16.9%
  5. 26 Mar 2026-49.6%
  6. 16 Mar 2026-4.7%

    Nothing announced by WVE that day or the session before.

  7. 8 Dec 2025+147.3%

Share of unusual movement by asset

For each asset, the share of WVE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
WVE-007
events and moves
4shown from 8 days
WVE-006
events and moves
3shown from 8 days
Bampidirsen
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—21%
Other company news (earnings, financing, releases naming no asset)—67%
Sessions with no dated event—13%

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 1/2
DMD exon 53RNA / oligonucleotide
Duchenne Muscular Dystrophy
Phase 1/2
Huntingtin (HTT)RNA / oligonucleotide
Huntington's Disease
Phase 1/2
SERPINA1 Z-allele mRNA (ADAR-mediated editing)RNA / oligonucleotide
Alpha-1 Antitrypsin Deficiency
Phase 1/2
INHBE (Inhibin beta E chain / Activin E)RNA / oligonucleotide
Obesity

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
September 2027 (1)
WVE-006Phase 1/2Alpha-1 Antitrypsin Deficiency
Est. primary completion 2027-09 · NCT06405633 · CT.gov ↗
What to watch
December 2027 (1)
WVE-007Phase 1/2Overweight and Obesity
Est. primary completion 2027-12 · NCT06842186 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
BampidirsenPhase 2Duchenne Muscular Dystrophy
Est. primary completion 2029-03 · NCT07209332 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 May 2026Topline resultWVE-006RestorAATion-2 (NCT06405633) multidose update: total AAT 13.6 uM at 400 mg, MZ-like levels with biweekly and monthly dosing
26 March 2025Topline resultWVE-N531FORWARD-53 (NCT04906460) 48-week data: mean dystrophin 7.8% and Time-to-Rise benefit vs natural history
Wave Life Sciences Ltd. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$13M$54M$197M+ $233M short-term inv.$62M-$60M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$2.3M$51M$368M+ $123M short-term inv.$69M-$54M operating cash flowreport ↗
2026-Q1$38M$47M$545M$26M-$60M operating cash flowreport ↗
2025-Q3—$46M$196M$54M-$45M operating cash flowreport ↗
2025-Q2$8.7M$43M$208M$50M-$46M operating cash flowreport ↗
2025-Q1$9.2M$41M$243M$47M-$63M operating cash flowreport ↗
2024-Q3—$41M$311M$62M-$46M operating cash flowreport ↗
2024-Q2$20M$40M$154M$33M-$27M operating cash flowreport ↗
2024-Q1$13M$33M$181M$32M-$33M operating cash flowreport ↗
2023-Q3$49M$32M$140M—-$34M operating cash flowreport ↗
2023-Q2$22M$33M$173M$21M-$37M operating cash flowreport ↗
2023-Q1$13M$31M$208M$27M$86M operating cash flowreport ↗
2022-Q3$0.3M$28M$97M+ $25M short-term inv.$39M-$26M operating cash flowreport ↗
2022-Q2$0.4M$30M$123M+ $25M short-term inv.$41M-$29M operating cash flowreport ↗
2022-Q1$1.8M$27M$62M+ $50M short-term inv.$38M-$40M operating cash flowreport ↗
2021-Q3$36M$31M$124M$6.2M-$28M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$43M$183M$602M+ $0 short-term inv.$51M-$187M operating cash flowreport ↗

Wave Life Sciences reported full-year 2025 revenue of $42.73M, down 60.5% YoY, with R&D spend of $182.78M, up 14.5% YoY. The company ended the year with cash and equivalents of $602.07M and reported a net loss of $204.38M.

Management guided to a cash runway into 3Q 2028 and highlighted ongoing clinical progress: WVE-007 data updates from the INLIGHT study are expected in 1Q 2026, with a Phase 2a multidose portion planned for 1H 2026 and additional trials as an incretin add-on and post-incretin maintenance in 2026. WVE-006 regulatory feedback on a potential accelerated approval pathway is anticipated mid-2026, with 400 mg multidose data expected in 1Q 2026; a CTA submission for WVE-008 is planned for 2026, and an NDA filing for WVE-N531 remains on track for 2026. Additionally, GSK selected a fourth development candidate under the collaboration, with up to $2.8 billion in potential milestones.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$108M$160M$302M$24M-$151M operating cash flowreport ↗
2023-FY$113M$130M$200M$14M-$19M operating cash flowreport ↗
2022-FY$3.6M$116M$89M$40M-$128M operating cash flowreport ↗
2021-FY$41M$122M$151M$31M-$89M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 5 purchases ($82.6M), 46 sales ($16.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-05Wagner Heidi L · directorAward / grant10,700——Form 4
2026-10-05TAKANASHI KEN · directorAward / grant10,700——Form 4
2026-10-05HENRY CHRISTIAN O · directorAward / grant10,700——Form 4
2026-10-05Rawcliffe Adrian · directorAward / grant10,700——Form 4
2026-10-05CORRIGAN MARK · directorAward / grant10,700——Form 4
2026-10-05Tan Aik Na · directorAward / grant10,700——Form 4
2026-10-05Verdine Gregory L. · directorAward / grant10,700——Form 4
2026-10-05RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% ownerAward / grant10,700——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 228 reporting institutions held 172.6M shares ($1.2B, 87.5% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.26,975,505$195.6M
2GSK plc18,245,691$132.3M
3BlackRock, Inc.14,117,412$102.4M
4MAVERICK CAPITAL LTD10,161,399$73.7M
5Driehaus Capital Management LLC5,431,021$39.4M
6FEDERATED HERMES, INC.5,317,457$38.6M
7FMR LLC5,192,761$37.6M
8683 Capital Management, LLC4,900,000$35.5M
9PRIMECAP MANAGEMENT CO/CA/4,832,952$35.0M
10M28 Capital Management LP4,588,284$33.3M
11STATE STREET CORP3,674,033$26.6M
12GEODE CAPITAL MANAGEMENT, LLC3,579,099$26.0M
13Siren, L.L.C.2,450,000$17.8M
14CITADEL ADVISORS LLC2,202,856$16.0M
15TWO SIGMA INVESTMENTS, LP1,878,115$13.6M